FoxC1 Antibody

Flow Cytometry: FoxC1 Antibody [NB100-1268]

Flow Cytometry: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed HEK293 cells (blue line), permeabilized with 0.5% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL. IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.

Knockdown Validated: FoxC1 Antibody [NB100-1268]

Knockdown Validated: FoxC1 Antibody [NB100-1268] - Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 and treated with DMSO or GSK-126 (2uM for 72h). a-Tubulin was used as a loading control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.

Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] -

Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] - Breast Cancer subtype specificity of the EZH2/FOXC1 metastatic axis. a Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 & EZH2. Scale bar is 100 μm. b Significant negative correlation between FOXC1 transcript levels & EZH2 protein levels (Total intensity) quantified by immunofluorescence in human Luminal B patient samples (r = −0.52, p = 0.02). Eight different fields taken with a ×20 objective were quantified per sample. c Kaplan–Meier survival curve of relapse-free survival (RFS) of 1142 luminal B tumours with high or low FOXC1 (log rank p = 0.001). d Correlation between FOXC1 mRNA levels & the FOXC1 Signature in a cohort of 385 Luminal B patients from publicly available TCGA Breast Cancer data set. e Kaplan–Meier analysis of relapse-free survival of 1142 Luminal B tumours with high or low FOXC1 gene signature expression (log rank p = 0.0044). RFS relapse-free survival Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FoxC1 Antibody [NB100-1268] -

Western Blot: FoxC1 Antibody [NB100-1268] - Ectopic expression of Foxc1 alters invasion but not proliferation. a Transwell invasion assay of PyVmT cells expressing exogenous Foxc1 or GFP. Experiments were performed three times, & results are displayed relative to untreated parental cell. *p < 0.05, Student’s two tailed t-tests. b CyQUANT assay measuring cellular proliferation of PyVmT cells expressing exogenous GFP or Foxc1. R.F.U relative fluorescence units. Data were normalized to the fluorescence values at time = 0. c Enumeration of lung lesions following the injection of PyVmT cells expressing exogenous Foxc1 or GFP in the tail vein of athymic nude mice. *p < 0.05, Student’s two tailed t-tests. Scale bar is 5 mm. d Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 & treated with DMSO or GSK-126 (2 μM for 72 h). alpha-Tubulin was used as a loading control. Right: Transwell invasion assay of PyVmT cells infected with shRNA targeting LacZ (control) or two different sequences targeting Foxc1. Cells were pre-treated with DMSO or GSK-126 (2 μM) for 72 h & assayed for their capacity to invade through Matrigel. All assays were performed in triplicate. *p < 0.05, Student’s two tailed t-tests Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.